EMA has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe thyroid eye disease.
Thyroid eye disease (TED), also known as Graves’ eye disease, is a rare autoimmune disease that triggers inflammation of muscles, fat, and other tissues around and behind the eyes. This can cause the eyes to bulge (or protrude), and other symptoms, including puffy eyelids, eye redness and irritation, eye pain, double vision, and eyelid retraction (when the upper and/or lower eyelids are pulled back more than normal). In severe cases, TED can cause vision loss and facial disfigurement.
Treatment options for moderate-to-severe TED are limited and most patients are treated with corticosteroids, with some patients needing multiple reconstructive surgeries…
